Cargando…
Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation
ABSTRACT: Ruxolitinib is an anti‐inflammatory drug that inhibits the Janus kinase‐signal transducer (JAK‐STAT) pathway on the surface of immune cells. The potential targeting of this pathway using JAK inhibitors is a promising approach in patients affected by coronavirus disease 2019 (COVID‐19). Rux...
Autores principales: | Mortara, Andrea, Mazzetti, Simone, Margonato, Davide, Delfino, Pietro, Bersano, Chiara, Catagnano, Francesco, Lauriola, Marinella, Grosso, Paolo, Perseghin, Gianluca, Ippoliti, Giovanbattista |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212747/ https://www.ncbi.nlm.nih.gov/pubmed/33403775 http://dx.doi.org/10.1111/cts.12971 |
Ejemplares similares
-
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19
por: Lauriola, Marinella, et al.
Publicado: (2020) -
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
por: Margonato, Davide, et al.
Publicado: (2020) -
Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022) -
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021) -
Leukocytoclastic Vasculitis as a Complication of Recombinant Granulocyte Colony-Stimulating Factor Therapy in a Heart Transplant Patient
por: Ippoliti, Giovanbattista, et al.
Publicado: (2014)